Tracers / [18F]FPIA
[18F]FPIA
Also written as 18F-pivalate; [18F]Fluoropivalate; [18F]fluoropivalic acid; [18F]FPIA; [18F]RAD101; [F-18]Fluoropivalate; [F-18]FPIA
- Radionuclide
- F-18 t½ 109.7 min
- Modality
- PET
- Production route
- Cyclotron liquid target
- Stage
- Clinical research
- Syntheses indexed
- 4
What it is
- Compound class
- Short-chain fatty acid
- Target / mechanism
- Short-chain fatty acid uptake and metabolism PMID 32123971 / DOI 10.1007/s00259-020-04724-y
- Clinical application
- Oncology imaging, particularly brain tumours (glioma) and brain metastases PMID 37490079; PMID 32123971 / DOI 10.1007/s00259-020-04724-y
- Theranostic pair
- —
Regulatory status
- FDA
- No Drugs@FDA / openFDA drug registry — no approved application found; search: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process&searchTerm=fluoropivalate
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| FASTlab GE HealthCare | vendor cassette | SPE | 30.3 ± 2.3% no | > 98% | methyl 2,2-dimethyl-3-(tosyloxy)propanoate | 41863729 2026 EJNMMI Radiopharm Chem Automated second-generation radiosynthesis of [18F]FPIA on the GE FASTLab™ platform — Non-decay-corrected radiochemical yields (RCY, n.d.c) were 30.3 ± 2.3% (n = 8) and 25.8 ± 6.6% (n = 46) on GE FASTlab™ and Trasis AIO™, respectively. |
| AllinOne (AiO) Trasis | vendor cassette | SPE | 25.8 ± 6.6% no | 99.7 ± 0.3% | methyl 2,2-dimethyl-3-(tosyloxy)propanoate | 41863729 2026 EJNMMI Radiopharm Chem Automated second-generation radiosynthesis of [18F]FPIA on the Trasis AIO™ platform — Non-decay-corrected radiochemical yields (RCY, n.d.c) were 30.3 ± 2.3% (n = 8) and 25.8 ± 6.6% (n = 46) on GE FASTlab™ and Trasis AIO™, respectively. |
| — | — | — | 25.4 ± 3.8% | >99% | — | 41616584 2026 Nucl Med Biol an optimized two-step, one-pot synthesis of [18F]FPIA using a vial-based automated synthesizer — 25.4 ± 3.8% (n = 9) activity yield at end of synthesis (EOS) |
| — | — | — | 37 ± 9% | > 99% | — | 41616584 2026 Nucl Med Biol an optimized two-step, one-pot synthesis of [18F]FPIA using a vial-based automated synthesizer — the scale-up synthesis was successful with a 37 ± 9% (n = 37) activity yield at EOS |
Need this precursor?We can point you to suppliers for [18F]FPIA, or handle the enquiry for you.
Get in touchQuality control Preliminary — inferred from compound class
- Ph. Eur. monograph
- —
- USP monograph
- —
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); organic-phase radiosynthesis assumed from isotope/compound class, no synthesis data confirming it -> GC residual solvents (preliminary); conventional nucleophilic 18F-fluorination assumed from isotope/compound class, no synthesis data confirming K222 use -> Kryptofix test (preliminary); STAGE 17.4 recheck by compound class ('Short-chain fatty acid'): HPLC UV -> HPLC cond. (aliphatic fatty acid, no aromatic ring -- weak UV chromophore, same category as acetate/citrate)
Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived
Setting up quality control?We can help you scope the equipment needed to release [18F]FPIA.
Get in touch